DanielEdmonstonMD

Assistant Professor of Medicine, Duke University School of Medicine | Nephrologist, Duke University Hospital | Faculty, Duke Clinical Research Institute

Join to view full profile

Dr. Edmonston is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Edmonston's full profile

Already have an account?

Office
300 W. Morgan Street
Office 522
Durham, NC 27701

Education & Training

Duke University HospitalFellowship, Nephrology, 2016
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2013 - 2016
Mercer University School of MedicineClass of 2013

Certifications & Licensure

NC State Medical License 2016 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Nephrology

Publications & Presentations

PubMed

Glucarpidase for Treatment of High-Dose Methotrexate Toxicity.
Shruti Gupta, Sarah Allison Kaunfer, Kevin L Chen, Julie-Alexia Dias, Anitha Vijayan
Blood. 2025-01-06
6 citations
Klotho and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
Daniel Edmonston, Michaela A A Fuchs, Emily J Burke, Tamara Isakova, Myles Wolf
American Journal of Kidney Diseases. 2024-09-01
1 citations
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, Karen Chiswell, Zachary Lampron
Journal of the American College of Cardiology. 2024-08-20

Press Mentions

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 DiabetesAugust 19th, 2024
Kidney, CV Outcomes Similar for SGLT2 Inhibition vs. GLP-1s for DiabetesAugust 12th, 2024
Highlights from the June 2021 IssueJune 1st, 2021
Join now to see all